MedMira, Inc.
MedMira Receives U.S. FDA Breakthrough Device Designation for Its Multiplo(R) Complete Syphilis (TP/nTP) Antibody Test
FDA recognition marks a significant regulatory milestone for MedMira's innovative, instrument-free point-of-care diagnostic technology.